Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nigella sativa vs Metformin in Prediabetes
NCT03925714Phase 3Recruiting
- Start
- Apr 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nigella sativa in prediabetes. Primary endpoint: Number of patients with improved insulin resistance at 26 weeks. Started Apr 2019; status: recruiting.
02
Drugs
nigella sativa
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT03925714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925714.